P12.11 RECQL4 promotes immune evasion and limits response to anti-PD-1 therapy and survival in melanoma patients

• M Mann,
• S Horn,
• D Schadendorf,
• S Egea-Rodriguez,
• R Váraljai,
• TM Nordmann,
• R Lubis,
• M Philip,
• F Rambow,
• A Roesch,
• B Klebl,
• ID Hickson,
• I Helfrich

Affiliations

M Mann

Aff2 grid.418615.f0000 0004 0491 845XInstitute of BiochemistryMax-Plank-Institute München Germany

S Horn

1Faculty of Nursing, University of Calgary, Calgary, Canada

D Schadendorf

1Dermatology, University Hospital Essen, Essen, Germany

S Egea-Rodriguez

3Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany

R Váraljai

3Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany

TM Nordmann

5Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany

R Lubis

6Lead Discovery Center GmbH (LDC), Dortmund, Germany

M Philip

3Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany

F Rambow

7Department of Applied Computational Cancer Research, Institute for AI in Medicine (IKIM), University Hospital Essen, University Duisburg-Essen, Essen, Germany

A Roesch

3Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany

B Klebl

6Lead Discovery Center GmbH (LDC), Dortmund, Germany

ID Hickson

8Center for Chromosome Stability and Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark

I Helfrich

1Department of Dermatology and Allergy, University Hospital of Munich, Ludwig-Maximilian-University (LMU), Munich, Germany